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Endothelial cells (ECs) express a Nox2 enzyme, which, by
generating reactive oxygen species (ROS), contributes to EC
redox signaling and angiotensin II (AngII)-induced endothelial
dysfunction. ECs also express abundantly an adenosine A2A
receptor (A2AR), but its role in EC ROS production remains
unknown. In this study, we investigated the role of A2AR in the
regulation of Nox2 activity and signaling in ECs with or with-
out acute AngII stimulation. In cultured ECs (SVEC4–10),
AngII (100 nM, 30 min) significantly increased Nox2 mem-
brane translocation and association with A2AR. These were
accompanied by p47phox, ERK1/2, p38 MAPK, and Akt phos-
phorylation and an increased ROS production (169 0.04%).
These AngII effects were inhibited back to the control levels by
a specific A2AR antagonist (SCH58261), or adenosine deami-
nase, or by knockdown of A2AR or Nox2 using specific siRNAs.
Knockdown of A2AR, as determined byWestern blotting, de-
creased Nox2 and p47phox expression. In wild-type mouse
aorta, SCH58261 significantly reduced acute AngII-induced
ROS production and preserved endothelium-dependent vessel
relaxation to acetylcholine. These results were further con-
firmed by using aortas from A2AR knock-out mice. In conclu-
sion, A2AR is involved in the regulation of EC ROS production
by Nox2. Inhibition or blockade of A2AR protects ECs from
acute AngII-induced oxidative stress, MAPK activation, and
endothelium dysfunction.
Endothelial cell (EC)2 metabolism produces abundant
adenosine, which signals through its four subtypes of G pro-
tein-coupled cell surface receptors (A1R, A2AR, A2BR, and
A3R) and is involved in the regulation of vascular function (1,
2). Among these adenosine receptors, A2AR has been found to
be extensively expressed in vascular ECs and had been widely
reported to play a major role in mediating adenosine-induced
endothelium-dependent vessel relaxation (3). Knock-out of
A2AR reduced aortic relaxation and endothelial function in
mice (4). However, this notion has been challenged by studies
showing that A2AR was not involved in the relaxation of the
isolated mouse aorta to adenosine and its analogues (5) and
was not involved in mediating adenosine-induced Ca2 influx
in ECs, which is crucial for endothelium-dependent vessel
relaxation (6).
ECs also express constitutively an NADPH oxidase (Nox),
which, by generating reactive oxygen species (ROS) as second
messengers, contributes to the regulation of EC function (7).
The Nox enzyme comprises a cytochrome b, which can be
further divided into one catalytic subunit (a member of the
Nox family) and one p22phox. To date, five members of the
Nox family have been identified (Nox1–5) (8), and Nox2
and Nox4 are the major Nox isoforms expressed in ECs and
represent important enzymatic sources of EC ROS produc-
tion (7, 9, 10). Nox2 is a highly glycosylated protein and re-
quires the presence of regulatory subunits, i.e. p40phox,
p47phox, p67phox, and rac1, for its activation (11). In response
to pathophysiological stimulations such as shear stress, angio-
tensin II (AngII), or inflammatory cytokines (TNF), the ac-
tivity of Nox2 (but not Nox4) is up-regulated, and excessive
ROS production from Nox2 outstrips endogenous antioxidant
defense and causes EC dysfunction (7, 12).
Several studies have reported a role of A2AR in the regula-
tion of ROS production by Nox2 enzyme, although the out-
comes differed from one organ to another. For example, in
neutrophils A2AR deficiency caused Nox2 activation, and in-
creased O2. production exacerbated inflammatory responses
and caused oxidative damage to tissues (13). In the lung,
knock-out of A2AR increased tracheal ROS production from
Nox2, which compromised tracheal relaxation in allergic mice
(14). However, in the context of neurodegerative diseases,
blockade of A2AR appeared to be beneficial in reducing oxida-
tive damage (15). Similar results were found in the heart
where genetic knock-out or pharmacological blockade of the
A2AR decreases cardiac ROS production from Nox2 enzyme
(16). Many patients suffering from neurodegenerative diseases
have endothelial dysfunction characterized by excessive ROS
production from Nox2 enzyme (17), and it is possible that
A2AR blockade might be beneficial in these endothelial dys-
function-related neurodegenerative and cardiovascular dis-
eases. This hypothesis has been supported by a recent study
showing that knock-out of A2AR protects ApoE knock-out
mice from atherosclerosis (18).
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AngII has pleiotropic acute and chronic effects on many
cell types and plays an important role in the pathophysiology
of cardiovascular diseases, including hypertension, atheroscle-
rosis, and heart failure (19). AngII is also a potent activator of
Nox2, and increased ROS production contributes to AngII-
induced EC dysfunction and vessel constriction (19). In the
present study, we investigated in detail the effects of A2AR
blockade or knockdown on basal and acute AngII-induced
endothelial ROS production by Nox2 and on redox-signaling
in cultured ECs and in mouse aortas isolated from wild-type
(WT) and A2AR knock-out (KO) mice.
EXPERIMENTAL PROCEDURES
Materials and Reagents—Affinity-purified rabbit polyclonal
antibodies to p40phox and Nox2 were kindly provided by Dr.
F. Wientjes (University College London, UK). Polyclonal anti-
bodies against p22phox, Nox2, Nox4, p40phox, p47phox, p67phox,
rac1, and A2AR were from Santa Cruz Biotechnology. Anti-
bodies to phospho-ERK1/2, phospho-p38 MAPK, phospho-
JNK, and phospho-Akt were from Cell Signaling Technology.
DHE (dihydroethidium) was purchased from Invitrogen.
SCH58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazole-
[4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine), CGS21680, (2-[4-(2-
carboxyethyl)phenethylamino]-5-N-ethylcarboxamidoad-
enosine), and other reagents and chemicals were from Sigma
unless stated otherwise.
Animals—WT and A2AR KO male CD1 mice at 10–12
weeks of age were used for aorta isolation. All studies were
performed in accordance with protocols approved by the
Home Office under the Animals (Scientific Procedures) Act
1986 UK.
Cell Culture and Cell Stimulation—The mouse lymph node
microvascular endothelial cell line (SVEC4–10) was obtained
from the American Type Culture Collection and grown in
Dulbecco’s modified Eagle’s medium (DMEM), containing
10% (v/v) heat-inactivated fetal calf serum, 100 IU of penicil-
lin, and 100 mg/ml streptomycin. Cells were seeded on the
day before the experiment to achieve90% confluence and
preincubated with vehicle (5% FCS/DMEM or 5%FCS/
DMEM/0.5% dimethyl dulfoxide) as control or with a selec-
tive A2AR antagonist (SCH58261, 100 nM dissolved in 0.5%
dimethyl sulfoxide) or adenosine deaminase (2 units/ml in 5%
FCS/DMEM) or a selective A2AR agonist CGS21680 (100 nM
in 5% FCS/DMEM/0.5% dimethyl sulfoxide) for 30 min. 100
nM AngII was added after that and incubated for 30 min in the
presence of SCH58261 or adenosine deaminase or CGS21680.
Cells were washed three times with PBS and scraped into ice-
cold Hanks’ balanced salt solution supplemented with 0.8 mM
MgCl2 and 1.8 mM CaCl2. Cells were disrupted by rapid freez-
ing in liquid nitrogen followed by homogenization and soni-
cation. Cell homogenates were used for measuring ROS pro-
duction or for immunoblotting.
In Vitro Knockdown of A2AR and Nox2 Using siRNAs—
These experiments were performed as described previously
(9). The control siRNA and A2AR siRNA were purchased
from Santa Cruz Biotechnology. The nucleotide sequences of
Nox2 siRNA and a random negative control siRNA were ex-
actly as described previously (20) and synthesized by VWR
International, LLC. Lipofectamine 2000 plusTM (Invitrogen)
was used as a transfection reagent in serum-free DMEM as
described previously (9). Forty-eight hours after the transfec-
tion, cells were used for further experiments.
ROS Production—O2. production by homogenates of cul-
tured cells was measured using lucigenin (5 M)-enhanced
chemiluminescence (BMG Lumistar, Germany) as described
previously (16). O2. production was expressed as arbitrary
mean light units/min measured over 20 min. The specificity
of O2. thus measured was confirmed by adding 10 mM tiron, a
nonenzymatic scavenger of O2. , to quench the O2. -dependent
chemiluminescence. Other enzymatic sources of O2. produc-
tion were also identified by preincubation of homogenates
with inhibitors such as N--nitro-L-arginine methyl ester (100
M), rotenone (50 M), oxypurinol (100 M), and diphenyl-
eneiodonium (20 M).
As alternative approaches, ROS generation in adherent
cells or in aorta sections with or without AngII (30 min) stim-
ulation were also measured by 2.7-dichlorofluorescein (200
nM) or DHE (2 M) fluorescence, respectively (9). Images were
captured under confocal microscopy, and the fluorescence
intensity was quantified from at least three random fields
(1,024 1,024 pixels) per slide, from three slides per experi-
mental condition. Experiments were repeated at least three
times for cell cultures or using aortic sections from at least six
animals.
Immunoblotting—This was performed exactly as described
previously (9). Equal amounts of protein from different sam-
ples were loaded, and -tubulin in the same sample was used
as a loading control. The blots were then developed using
ECL reagent (Amersham Biosciences), and images were cap-
tured using an imaging system (UVP BioImager) and quanti-
fied. For the quantification of AngII-induced MAPK and Akt
phosphorylation, the levels of phosphorylated specific bands
were normalized to the levels of the same total protein de-
tected in the same sample.
Immunofluorescence Confocal Microscopy—Experiments
were performed as described previously (16). Briefly, cells
were cultured onto chamber slides and fixed, and slides were
coated. Primary antibodies were used at 1:250–500 dilution in
PBS with 0.1% BSA for 30 min at room temperature. Biotin-
conjugated anti-rabbit or anti-goat (1:1,000 dilution) were
used as secondary antibodies. Specific binding was detected
by extravidin-FITC or streptavidin-Cy3. Images were ac-
quired on a Zeiss LS510 confocal microscopy system.
Aorta Organ Bath Experiments—Thoracic aortas (n 9
mice) were carefully dissected free from surrounding fat tis-
sue and cut into 3–4-mm-long rings. The aorta rings were
incubated at 37 °C with 200 nM AngII in serum-free DMEM
in the presence or absence of either 100 nM SCH58261 or 20
mM tiron for 45 min. Aortic rings were then suspended in an
organ bath (37 °C) containing Krebs-Henseleit solution (119
mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5
mM CaCl2, 25 mM NaHCO3, 11.1 mM glucose, pH 7.4) gassed
with 95% O2/5% CO2, and connected to isometric force dis-
placement transducers. Endothelium-dependent relaxation to
acetylcholine (0.001–10 M added cumulatively) and endo-
thelium-independent vessel relaxation to sodium nitroprus-
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side (0.0001–1 M added cumulatively) were tested in rings
preconstricted to 70% of their maximal phenylephrine
(0.001–10 M added cumulatively)-induced tension.
Statistics—Data were presented as means S.D. from at
least three experimental results taken from three independent
cell cultures for each condition. In the case of the organ bath
studies, nine mice were used, and the data presented are the
mean S.D. from these results. Comparisons were made by
an unpaired t test, with Bonferonni correction for multiple
testing. p 0.05 was considered statistically significant.
RESULTS
Effects of A2AR Blockade on EC ROS Production and
Signaling—To assess the effects of A2AR blockade on EC ROS
production, we treated cells with a selective A2AR antagonist
SCH58261 (100 nM for 60 min) and examined the NADPH-
dependent O2. production by lucigenin chemiluminescence
(Fig. 1, A and B). There was a basal level of O2. production by
cells maintained in culture medium only. Treatment of cells
with SCH58261 slightly but significantly reduced basal (with-
out AngII) NADPH-dependent O2. production. AngII (100 nM
for 30 min) stimulation significantly increased O2. production,
and this was significantly inhibited by diphenyleneiodonium
(82 1.9%, a flavoprotein inhibitor) and tiron (61 1.5%, an
O
2
. scavenger) but not by oxypurinol (a xanthine oxidase in-
hibitor), or N--nitro-L-arginine methyl ester (a nitric oxide
synthase inhibitor). There was a slight but significant reduc-
tion in ROS levels by rotenone (21 9%, an inhibitor of mito-
chondria complex-1 enzymes) suggestive of some low level
involvement of mitochondria (data not shown).
AngII-induced ROS production was inhibited back to the
control levels in the presence of SCH58261. When cells were
treated with AngII plus SCH58261, the inhibitory effect of
diphenyleneiodonium on ROS production was reduced to
49 8%, but the inhibition by rotenone remained the same
(24 9%) (Fig. 1A, right). These data suggested that the in-
hibitory effect of SCH58261 was on flavoproteins but not on
mitochondrial enzymes. We examined also the effect of aden-
osine depletion by pretreatment of ECs with 2 units/ml aden-
osine deaminase. Similar to the SCH58261 effect, depletion of
adenosine significantly reduced both basal and the AngII-
induced EC O2. production (Fig. 1B, center). Preincubation of
ECs with a selective A2AR agonist CGS21680 (100 nM) had no
significant effect on the basal or the acute AngII-induced ROS
production (Fig. 1B, right).
As an alterative method, we detected ROS production
(without adding NADPH) by in situ DCF fluorescence on ad-
herent ECs (Fig. 1C). Similar to the results from lucigenin
chemiluminescence, treatment of cells with SCH58261 signif-
icantly reduced the basal DCF fluorescence. AngII stimulation
significantly increased the DCF fluorescence, and this in-
crease was significantly inhibited back to control levels in ECs
treated with SCH58261. The detection of O2. was confirmed
by using tiron, a cell membrane-permeable O2. scavenger,
which almost abolished the DCF fluorescence.
The effects of the A2AR antagonist SCH58261 on AngII-
induced redox-sensitive MAPK and Akt activation were in-
vestigated using specific monoclonal antibodies against phos-
pho-ERK1/2, phospho-p38 MAPK, phospho-JNK and
phospho-Akt (Fig. 2). There was some level of phosphoryla-
tion of ERK1/2 and p38 MAPK detected in the control cells,
and the levels of their phosphorylation were significantly less
in cells treated with SCH58261. AngII stimulation (30 min)
increased ERK1/2 and p38 MAPK phosphorylation signifi-
cantly, and these AngII effects were absent in cells pretreated
with SCH58261 (Fig. 2A). Similarly, AngII stimulation caused
significant Akt phosphorylation, and this was completely in-
hibited by SCH58261. The levels of phosphorylated JNK were
very low, and it was hard to see any changes.
p47phox phosphorylation and binding to Nox2 have been
found to be a prerequisite of Nox2 enzyme activation (19). To
explore the link between A2AR blockade to ERK1/2 and p38
MAPK inactivation, and the inhibition of Nox2-derived ROS
production, we immunoprecipitated down the p47phox and
examined the effects of A2AR blockade on AngII-induced
p47phox serine phosphorylation and the complex formation
with Nox2. We found that SCH58261 significantly reduced
the levels of both basal (without AngII) and AngII-induced
p47phox phosphorylation, and this resulted in a significant
reduction of Nox2 co-immunoprecipitated down with p47phox
(Fig. 2B). These results indicated that reduced ROS produc-
tion by A2AR blockade was due to the inhibition of p47phox
phosphorylation and Nox2 activation.
AngII-induced Nox2 Membrane Translocation and Asso-
ciation with A2AR—Nox2 has been reported to translocate
to the EC membrane in response to AngII stimulation (7,
12); therefore, we investigated the potential link between
Nox2 and A2AR in response to AngII stimulation by two-
way co-immunoprecipitation. We immunoprecipitated
down A2AR and detected the presence of Nox2 and then
confirmed this by immunoprecipitating down Nox2 and
detecting the presence of A2AR. We found no changes in
the level of membrane A2AR expression in response to
acute AngII stimulation. However, there were significant
increases in the levels of membrane Nox2 expression and
association with the A2AR (Fig. 2C). The purity of the
membrane preparation was confirmed by the positive ex-
pression of CD31, which is an EC surface marker, and the
negative expression of peroxisome proliferator-activated
receptor , which is a nuclear receptor.
Effects of A2AR Knockdown on Nox2 Expression, ROS Pro-
duction, and AngII Signaling—To define further the role of
A2AR in acute AngII-induced ROS production by Nox2 en-
zyme and endothelial dysfunction, we performed in vitro
transient knockdown of A2AR using siRNA and examined the
protein levels of A2AR, Nox2, Nox4, and p22phox and the regu-
latory subunits of Nox2, i.e. p40phox, p47phox, p67phox, and
rac1 by immunoblotting (Fig. 3A). A2AR protein was detected
in cells transfected with a scrambled control siRNA, and the
level of expression was significantly reduced to just detectable
in cells transfected with A2AR siRNA. Knockdown of A2AR
significantly reduced the protein levels of Nox2 and p47phox,
which is a major regulatory subunit of the Nox2 enzyme.
However, the levels of Nox4, p22phox, p40phox, p67phox, and
rac1 were not significantly affected by A2AR knockdown (Fig.
3A). We then looked at the NADPH-dependent ROS produc-
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tion and found that knockdown of A2AR significantly reduced
both the basal and acute AngII-induced ROS production in
these cells (Fig. 3B, left). Parallel experiments with Nox2
siRNA further confirmed that AngII-induced ROS production
was from Nox2 enzyme. Thus, in vitro knockdown of Nox2
significantly reduced the basal ROS production and com-
pletely abolished the AngII-induced ROS production. Adding
SCH58261 significantly reduced AngII-induced ROS produc-
tion in cells transfected with control siRNA and had no effect
on cells tranfected with Nox2 siRNA (Fig. 3B, right).
FIGURE 1. EC ROS production. A, O2
. production detected by lucigenin chemiluminescence. Left panel, kinetic measurement of O2
. . NADPH was added after
20 min of measurement. Right panel, effect of different enzyme inhibitors on NADPH-dependent O2
. production in the presence of SCH58261. *, p 0.05 for
the indicated values versus the values without AngII. †, p 0.05 for the indicated values versus AngII values. #, p 0.05 for the indicated values versus val-
ues of AngII SCH58261. B, effects of SCH58261, adenosine deaminase (ADA), and CGS21680 on NADPH-dependent O2
. production measured by lucigenin
chemiluminescence.MLU, mean light unit. C, O2
. production by intact adherent cells detected by DCF fluorescence. *, p 0.05 for the indicated AngII values
versus vehicle control values. †, p 0.05 for indicated values versus the values without SCH58261 or adenosine deaminase or CGS21680 or tiron in the same
group. Error bars, S.D.
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FIGURE 2. Effects of SCH58261 on protein phosphorylation and expression. A, the levels of phospho-protein bands were quantified and normalized to
the levels of the total proteins detected in the same samples. B, p47phox was immunoprecipitated down and detected for serine phosphorylation and bind-
ing to Nox2. C, two-way immunoprecipitation for the detection of AngII-induced Nox2 association with A2AR is shown. *, p 0.05 for AngII values versus
vehicle controls. †, p 0.05 for SCH58261values versus values without SCH58261 in the same treatment group. Error bars, S.D.
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The effects of A2AR knockdown on acute AngII-induced
phosphorylation of MAPKs and Akt was also investigated
(Fig. 4). Supportive of the results with the A2AR antagonist,
SCH58261, knockdown of A2AR completely abolished AngII-
induced phosphorylation of ERK1/2, p38 MAPK, and Akt
compared with cells transfected with control siRNA. The level
of phosphorylated JNK was again almost undetectable. Put
together, our data strongly suggested that A2AR is involved in
FIGURE 3. Effects of A2AR siRNA on Nox2 expression and activity. A, protein bands were quantified and normalized to the levels of -tubulin detected in
the same samples. B, NADPH-dependent O2
. production detected by lucigenin chemilunescence.MLU, mean light unit. *, p 0.05 for indicated values ver-
sus vehicle control siRNA values. †, p 0.05 for indicated values versus control siRNA values in the same treatment group. Error bars, S.D.
FIGURE 4. Effects of A2AR siRNA onMAPK and Akt phosphorylation. The phospho-protein bands were quantified and normalized to the total levels of
the same proteins detected in the same samples. *, p 0.05 for AngII values versus values without AngII in the same group. †, p 0.05 for indicated values
versus AngII values in control siRNA group. Error bars, S.D.
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the regulation of endothelial ROS production by Nox2, and
this requires the ERK1/2, p38 MAPK and Akt signaling.
Blockade or knockdown of A2AR inhibited MAPK activation
and thereafter inhibited AngII effects on EC ROS production.
Effects of SCH57261 or Genetic knock-out of A2AR on Mouse
Aorta ROS Production and Relaxation—To clarify the in vivo
relevance of A2AR blockade by SCH58261 on vascular func-
tion, we freshly isolated mouse aortas, incubated the aortic
rings with or without 200 nM AngII (for 45 min) and then ex-
amined the ROS production by DHE fluorescence on vessel
sections. Tiron was used to confirm the detection of O2. (Fig.
5A). Similar to our cell culture experimental results, acute
AngII stimulation significantly increased DHE fluorescence
throughout the vessel wall, and SCH58261 treatment signifi-
cantly reduced both the basal and the AngII-induced DHE
fluorescence. Vessel structure was shown by hematoxylin and
eosin staining on parallel sections. Because ERK1/2 phospho-
rylation was a prominent response to acute AngII stimulation
in cell experiments, we looked at AngII-induced ERK1/2
phosphorylation in the sections of aortas pretreated with or
without SCH58261 (Fig. 5B). To help to visualize the endo-
thelium, the section was labeled with CD31 which is an EC
marker, and ERK1/2 phosphorylation was detected using a
specific monoclonal antibody. Compared with control vessels
FIGURE 5. ROS production and ERK1/2 phosphorylation in mouse aorta sections. A, ROS production detected by DHE fluorescence. Tiron (a specific O2
.
scavenger) was used to confirm the detection of O2
. . *, p 0.05 for AngII values versus vehicle values. †, p 0.05 for indicated values versus values in the
same treatment group without SCH58261 or tiron. n 6 animals. B, confocal images of ERK1/2 phosphorylation in aortic sections. CD31 (an endothelial
marker) was labeled in green (FITC), and phospho-ERK1/2 was labeled in red (Cy3). The yellow color inmerged images indicates ERK1/2 phosphorylation de-
tected in the endothelium. Error bars, S.D.
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treated with vehicle only, ERK1/2 phosphorylation was seen
throughout the vessel wall and strongly in the endothelium in
AngII-stimulated aortas, and this was largely inhibited in ves-
sels pretreated with A2AR antagonist SCH58261.
We then looked at the effects of SCH58261 on endotheli-
um-dependent vessel relaxation to acetylcholine using WT
aortic rings (Fig. 6A). Compared with control aortas, treat-
ment with 200 nM AngII (for 45 min) severely compromised
the endothelium-dependent vessel relaxation to acetylcholine.
Addition of 100 nM SCH58261 or 20 mM tiron during AngII
stimulation preserved endothelium-dependent vessel relax-
ation to acetylcholine back to the control levels. There was no
significant difference in vessel relaxation to sodium nitroprus-
side, an endothelium-independent vasodilator, under the
same treatments confirming that the SCH58261 effects were
on the endothelium not the vascular smooth muscle. (Fig. 6B).
To determine further the role of A2AR on promoting AngII-
induced ROS, we used aortas isolated from A2AR KO mice
and examined the ROS production by aorta homogenates.
Knock-out of A2AR significantly reduced AngII-induced ROS
production (Fig. 6C) and inhibited AngII impairment of endo-
thelium-dependent vessel relaxation to acetylcholine (Fig. 6D)
compared with WT vessel (Fig. 6A).
DISCUSSION
Endothelial dysfunction characterized by excessive ROS
production from Nox2 activation has been found to play an
important role in the pathogenesis of many cardiovascular
diseases such as hypertension and atherosclerosis. Therapies
that inhibit Nox2 activation are urgently required to protect
the endothelium from ROS damage. The present study pro-
vides the first evidence that inactivation of A2AR through
pharmacological blockade or in vitro knockdown or genetic
knock-out of A2AR effectively inhibits endothelial ROS pro-
duction from Nox2 and attenuates AngII-induced oxidative
stress, MAPK activation, and endothelial dysfunction.
A2AR are highly expressed on ECs (21). Classically, A2AR
activation in ECs was believed to mediate endothelium-de-
FIGURE 6. Effect of SCH58261 or A2AR KO on vessel relaxation. A, endothelium-dependent relaxation to acetylcholine of WT aortic rings. *, p 0.05 for
AngII values versus vehicle controls (left panel) or versus the values in the presence of SCH58261 or tiron (right panel). B, endothelium-independent relax-
ation to sodium nitroprusside (SNP)of WT aortic rings. C, NADPH-dependent ROS production detected by lucigenin chemiluminescence.MLU, mean light
unit. *, p 0.05 for AngII versus vehicle controls in WT. †, p 0.05 for A2AR KO versusWT treated with AngII. D, endothelium-dependent relaxation to acetyl-
choline (ACh) of A2AR KO aortic rings. Error bars, S.D.
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pendent vessel relaxation, and genetic A2AR deficiency has
been shown to result in loss of endothelium-mediated relax-
ation (3, 4). However, A2AR inactivation has been shown to
protect ApoE knock-out mice from atherosclerosis, which
may provide the potential for treating atherosclerosis (18).
Although the role of endothelial A2AR and the involvement of
Nox2-derived ROS production were not examined in that
particular study, a study from another group by cross-breed-
ing p47phox knock-out mice and ApoE knock-out mice dem-
onstrated a similar result of reduced atherosclerosis and
clearly pointed out a crucial role of Nox2-derived ROS in the
pathogenesis of atherosclerosis (22). Our study extends and
supports this suggestion and provides a novel possible mecha-
nism for this effect. In the current study we carried out a de-
tailed investigation on the effects of A2AR blockade on ROS
production by ECs. We found that treatment of cells with a
specific A2AR antagonist, SCH58261, significantly inhibited
ROS production from Nox2 and thereafter abolished acute
AngII-induced MAPK and Akt activation. We have also
shown that A2AR blockade inhibited AngII-induced p47phox
phosphorylation and complex formation with Nox2, which
are prerequisites for AngII-induced Nox2 activation and ROS
production (12). The removal of adenosine by adenosine
deaminase also reduced ROS production, which added fur-
ther evidence for the requirement of A2AR signaling for ROS
production. The lack of effect of the selective A2AR agonist
CGS21680 may be because (i) enough adenosine is already
present in the culture medium to activate the A2AR at its
maximum level, and this is supported by the experiment using
adenosine deaminase such that eliminating adenosine mimics
the effect of SCH58261 or (ii) an increase in A2AR activity
alone cannot promote further ROS production under culture
conditions.
The inhibitory effects of A2AR blockade on Nox2 activity
were further confirmed by showing that transient knockdown
of A2AR using siRNA reduced significantly the ROS produc-
tion and the protein expression of Nox2 and p47phox, but not
Nox4. Moreover, knockdown of Nox2 using siRNA com-
pletely abolished AngII-induced ROS production by EC. Simi-
lar results were obtained in vessel sections where SCH58261
inhibited AngII-induced ROS production as detected by DHE
fluorescence, and preincubation of vessels with SCH58261
attenuated AngII effects on impairing vessel relaxation and
preserved endothelial function. In line with these studies, we
found also that genetic knock-out of A2AR inhibited ROS pro-
duction in the aortas and preserved endothelial function.
AngII is the dominant effector of the renin-angiotensin
system and is implicated in the pathogenesis of disorders such
as hypertension, where one of the major mechanisms of its
effects is through oxidative damage to the endothelium due to
Nox2 activation (12). The present study is the first report to
demonstrate the potential of an A2AR antagonist to attenuate
acute AngII-induced Nox2 activation. Thus, in cultured EC or
in aortic vessels pretreated with SCH58261, AngII-induced
ROS production and MAPK and Akt activation were abro-
gated in particular in the endothelium, and SCH58261 or
knock-out of A2AR preserved endothelium-dependent vessel
relaxation to acetylcholine. Although vascular smooth muscle
cells are the predominant cellular component in the vessel
wall, Nox2 expression is very low or undetectable in vascular
smooth muscle cells.
Both the MAPK family and Akt are the downstream signal-
ing pathways of A2AR, via Gs/cAMP-dependent (1) or -inde-
pendent pathways (23), and ERK1/2 and p38MAPK have been
found to phosphorylate p47phox. Therefore, the potential
mechanistic link from A2AR blockade to the reduction of both
basal and AngII-induced Nox2 activation is that the A2AR
blockade inhibited MAPK activation and thereafter reduced
the levels of p47phox phosphorylation and binding to Nox2.
Long term A2AR inactivation (in the case of A2AR knock-
down) results in reduced Nox2 expression. Our data clearly
demonstrated that A2AR signaling is necessary to promote
AngII-induced MAPK and p47phox phosphorylation. Another
interesting observation from the current study is that AngII
induced Nox2 plasma membrane translocation and associa-
tion with A2AR, and this was confirmed by the two-way co-
immunoprecipitation of Nox2 or A2AR. A2AR has been found
to bind to several signaling molecules, including ERK1/2 and
p38 MAPK (24). The significance of AngII-induced Nox2 as-
sociation with A2AR requires further investigation.
In summary, we have reported for the first time that block-
ade of A2AR with an antagonist, SCH58261, removal of aden-
osine by adenosine deaminase, knockdown of A2AR using
siRNA, or genetical knock-out of A2AR effectively inhibited
basal and acute AngII-induced ROS production by Nox2 in
ECs. This in turn significantly protected endothelium func-
tion from AngII-induced oxidative damage. Antagonists to
A2AR may therefore have therapeutic potential to inhibit
Nox2 activation and to treat diseases related to endothelial
oxidative stress.
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